Journal of Pharmaceutical Sciences and Drug Development


Nisoldipine is a pharmaceutical drug used for the remedy of persistent angina pectoris and high blood pressure. It is a calcium channel blocker of the dihydropyridine class. It is offered in the United States below the proprietary name Sular. Nisoldipine has tropism for cardiac blood vessels. It became patented in 1975 and accepted for clinical use in 1990. Nisoldipine is contraindicated in human beings with cardiogenic surprise, volatile angina, myocardial infarction, and at some point of pregnancy and lactation. Common side outcomes are headache, confusion, speedy heartbeat, and edema. Hypersensitivity reactions are rare and encompass angioedema. The substance is metabolized by means of the liver enzyme CYP3A4. Consequently, CYP3A4 inducers such as rifampicin or carbamazepine should lessen the effectiveness of nisoldipine, while CYP3A4 inhibitors such as ketoconazole boom the quantity of nisoldipine in the frame more than 20-fold. Grapefruit juice additionally will increase nisoldipine concentrations through inhibiting CYP3A4.

Relevant Topics in Medical Sciences